News
-
Showcase
CMEF
We look back on a successful trade fair CMEF in Shanghai and would like to thank all visitors, business partners and our Chinese ANTON HIPP team. ...
-
Showcase
FDA Emerging Technology Program
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in ...
-
Showcase
Northern Arizona, Verde Valley MC Highlights VeraForm; Importance Marking Breast Surgical Site
As a patient facing breast cancer surgery, you should know that precise "marking" of your cancer surgical site is an important part of your treatment. A marker is a device inserted at the surgical site. Precision in marking helps make sure you retain as much normal breast tissue as possible with the surgery. This ultimately leads to best overall post-surgical care by your wellness team. A new ...
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Showcase
Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...
-
Showcase
Zeneo® Adrenaline: A New Innovative Formulation
Anaphylactic shock is an absolute medical emergency. When anaphylactic shock is suspected, emergency services must be called and emergency first aid administered immediately. The only first-line treatment for anaphylactic shock is injectable adrenaline1. In the USA: 1.6% to 5.1% of the population has experienced anaphylactic shock, 1% of hospitalizations are caused by it, 0.1% of patients ...
By Crossject
-
Showcase
Mojo Vision Reaches Significant Development Milestone for Smart Contact Lens
New prototype of Mojo Lens incorporates numerous industry-first features, including the world’s smallest and densest dynamic display, low-latency communication, and an eye-controlled user interface SARATOGA, Calif.--(March 30, 2022)--Mojo Vision, the Invisible Computing Company, today announced its most advanced prototype of Mojo Lens, the world's first true smart contact lens, including ...
-
Showcase
Corify Care raises €2.35M to translate its cardiac mapping technology to the market. .
- Corify Care is developing ACORYS®, a non-invasive cardiac mapping medical device to transform the cardiac arrhythmia treatment process. - The investment round is led by Clave Capital, counting with investment from CDTI through its Innvierte program and the support from Genesis Biomed. Corify Care, the developer of an innovative and completely non-invasive cardiac mapping system, ...
-
Showcase
Empatica Announces EmbracePlus: NASA Medical Quality in a Down-to-Earth Smart Watch
BOSTON, Nov. 19, 2019 /PRNewswire/ -- On November 19th, 2019, Empatica is announcing EmbracePlus, their new smart watch built in partnership with TRISH, the Translational Research Institute for Space Health. NASA's Human Research Program partners with external entities to develop new approaches that can help reduce the risk to humans on long exploration missions. One such entity is TRISH, who ...
-
Showcase
RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country
RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the development of national guidelines in ...
By RTsafe
-
Showcase
Are the patients able to perform the home spirometry with AioCare?
The Journal of Asthma published the results of a study that assessed asthma patients and their ability to perform high-quality daily spirometry with the AioCare system. The study has shown that home spirometry is safe without supervision and feasible for asthma patients. Abstract: Background: Self-management is an appealing strategy for the prevention of asthma exacerbations. This study aimed ...
By AioCare
-
Showcase
PhotoniCare Announces FDA Clearance for First-In-Class Technology for Imaging the Ear
Champaign, Ill. – Jan. 6, 2020 – PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its TOMi™ Scope [OtoSight Middle Ear Scope] for non-invasive imaging of the middle ear. Using optical coherence ...
-
Showcase
Koning Ends the Year with $2.6M Republic Raise
NORCROSS, Ga., Feb. 1, 2022 /PRNewswire/ -- Koning, a growing medical device startup company based outside Atlanta, had a successful conclusion to 2021. The company recently finished their first Republic crowdfunding campaign, exceeding capital targets, and raising over $2.6M in only 5 months. Koning's FDA breast screening trial is also underway with participating clinics in Daytona Beach, FL and ...
-
Revolutionising Cardiovascular Health: Monitoring the Surface Metallurgy of Stents
In a ground-breaking advancement for cardiovascular care, Hiden Analytical Ltd is proud to announce a surface measurement technique for devices critical in the treatment of heart disease. Utilizing the most sensitive surface analysis technology, Secondary Ion Mass Spectrometry (SIMS), Hiden Analytical is setting new standards in the safety, efficacy, and innovation of stent technology. Surgical ...
-
Improve Your Wellbeing with Remedial Massage in Hobart City: How to Find the Right Therapist
Welcome to the definitive resource to improving your wellbeing with remedial massage in Hobart City! If you want to eliminate stress, ease tension, and improve your overall health, you’ve come to the correct place. In this blog post, we’ll look at the many benefits of remedial massage and offer helpful advice on how to select the right therapist for you. So sit back, relax, and ...
-
Showcase
Arab Health
We look back on a successful trade fair Arab Health in Dubai, and would like to thank all visitors, business partners. ...
-
Showcase
Zeneo® Midazolam Earns The Orphan Drug Designation
The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes). The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. ...
By Crossject
-
Showcase
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
On March 15th 2015, Tim Buckinx’ son said: “Papa, you work in digital, can’t you create a light that turns on when my brain switches off?” At ten years old, he was simply fed up with the daily impact of his refractory epilepsy. That pain became a vision, and that vision became the Belgian digital therapeutics company epihunter, aimed at enabling people with a brain ...
By Epihunter NV
-
Showcase
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest that onapristone adds to inhibition ...
-
Showcase
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you